Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of microbial markers in the diagnosis and treatment effect evaluation of cerebral infarction

A technology of cerebral infarction and reagents, applied in the field of biomedicine, can solve the problems of high risk, difficult treatment, and high recurrence rate of cerebral infarction

Active Publication Date: 2021-07-16
THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, the recurrence rate of cerebral infarction is extremely high, and the risk of recurrence in a short period of time is greater and more difficult to treat
[0003] Statins (3-hydroxy-3-methylglutarphthalein coenzyme A reductase inhibitors) were initially included as lipid-lowering drugs in the secondary prevention of ischemic stroke and were widely used clinically. In-depth discovery of its role in the treatment of ischemic stroke does not stop there

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of microbial markers in the diagnosis and treatment effect evaluation of cerebral infarction
  • Application of microbial markers in the diagnosis and treatment effect evaluation of cerebral infarction
  • Application of microbial markers in the diagnosis and treatment effect evaluation of cerebral infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Biomarkers associated with cerebral infarction

[0050] 1. Experimental animals

[0051] Adult male C57BL / 6 mice (body weight 23.0 to 26.0 g, 8 to 12 weeks old) of a specific pathogen-free grade were purchased from Beijing Weitong Lihua. All C57BL / 6 mice were kept under specific pathogen-free conditions with relatively constant humidity (60%±5%) and temperature (22°C±3°C), light time of 12h / dark time of 12h, all Animals were given free access to food and water. The model of focal cortical cerebral infarction in mice was established by electrocoagulation, and the mice were randomly divided into two groups, the control group (pMCAO, 25 rats) and the medication group (25 rats).

[0052] 2. Drug intervention: Atorvastatin (Pfizer, USA) was dissolved in 0.9% normal saline at a concentration of 2 mg / ml. Give the drug 20mg / kg / d by intragastric administration. The cerebral infarction group was treated with an equal volume of normal saline. Fecal samples of the mi...

Embodiment 2

[0091] Embodiment 2 feces transplant experiment (FMT)

[0092] Fecal material from atorvastatin-treated mice was collected under aseptic conditions, and feces (0.1 g) from donor mice were mixed and suspended in 1 ml sterile PBS. The mixture was mixed for 15 s using a benchtop vortex (Vortex-Genie 2, Science Industries, USA), centrifuged at 800 g for 3 min at room temperature, and 500 μL of the supernatant was orally administered to PMCAO mice (n=12). Fresh feces were prepared on the day of fecal transplantation, within 15 minutes before gavage. Neurobehavior of FMT mice was measured and compared with pMCAO group (n=12).

[0093] The result is as image 3 As shown, after fecal transplantation, the neuroethology of mice was improved and the mNSS score was reduced ( image 3 A), increased Rotarod round time ( image 3 B), reducing the contact time in the adhesion removal experiment ( image 3 C) and removal time ( image 3 D).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of microbiological markers in the diagnosis of cerebral infarction and the evaluation of therapeutic effect, and the specific microbiological marker is Vampirovibrio. In the present invention, the drug intervention effect of the subject can be judged by detecting the abundance of Vampirovibrio in the subject sample. At the same time, the invention also provides the application of microbial markers in the treatment of cerebral infarction.

Description

technical field [0001] The application belongs to the field of biomedicine and relates to the application of microbial markers in the diagnosis of cerebral infarction and the evaluation of therapeutic effect. Background technique [0002] Cerebral infarction, also known as ischemic stroke, is one of the diseases with the highest incidence rate among cerebrovascular diseases. Data surveys show that the incidence rate, disability rate and mortality rate of cerebral infarction are very high, which seriously affects the quality of life of patients. . Cerebral infarction is a cerebrovascular disease caused by cerebral blood supply disturbance, and lacunar obstruction is the most common. The main features of cerebral infarction are acute onset, often accompanied by history of hypertension or emotional stimulation before the onset, dizziness, unsteady walking, and weakness of limbs. Severe disturbance of consciousness, sensory and motor dysfunction often occurs during the onset of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/689C12Q1/6883C12Q1/04G01N33/68C12R1/01
CPCC12Q1/6883C12Q1/689C12Q2600/106G01N33/6893G01N2800/2871
Inventor 张祥建张培培
Owner THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com